Alloy M4 Face Serum Rx: the serum record and the cream study

The page names estriol, peptides and hyaluronic acid. Its public product metadata provides the more detailed advertised specification: estriol 0.3%, palmitoyl pentapeptide-4 0.1%, acetyl hexapeptide-8 0.1% and hyaluronic acid 0.5%. The same metadata lists additional formula components and describes one bottle containing 45 grams as a three-month supply. Exact serum record.

These details improve the public description but are not an inspection or assay of an individually dispensed bottle. They also do not make a gram-based package equivalent to another provider's milliliter-based cream offer. The product-record guide explains that distinction without converting quantities into use instructions.

The prominent clinical block on the serum page explicitly says its improvements were seen with M4 Face Cream Rx compared with placebo. The public product metadata's clinical-results field names the cream too. That is a meaningful limitation: a shared estriol ingredient and brand family do not establish a result for the peptide-containing serum. Serum-page study wording.

The hydration-and-firmness guide separates different outcomes even within a study. This review does not relabel the cream's reported percentages as serum effects, add them together or treat a positive skin-feel report as independent confirmation of a structural change.

Alloy's updated study article describes a 12-week face-cream study involving 40 women. Its skincare collection page carries a 2024 study disclosure listing 86 participants. The reviewed summaries do not resolve how those population figures relate. They may refer to different reporting sets or records, but we cannot establish that from the text and do not invent an explanation. Company study account and collection disclosures.

This is a source limitation, not proof that no study occurred. It means the exact protocol, population and analysis would be needed before reconciling the numbers. None of that uncertainty supplies missing serum-specific evidence.

We reviewed the company’s narrative and disclosures rather than an independently obtained full report with its complete methods, exclusions and analysis. That limits how confidently the named percentages can be interpreted even for the cream, before considering a different serum.

The serum page makes a broad claim that topical estriol stays at the skin surface and does not enter the bloodstream. Its safety copy also presents compatibility with other hormone treatment. Those company statements are not adopted here as proof of absent absorption, universal compatibility or risk-free use. Alloy product claims.

FDA states that there are no FDA-approved estriol drugs and has not established estriol products as safer forms of estrogen. The estrogen-identity guide explains why a facial use does not replace a prescriber's review of the exact product and medical context. FDA estriol information.

The serum page lists $159 for a three-month supply, with free delivery and included unlimited doctor access. A card in Alloy's study article expresses the same offer as $53 per month while stating it is billed at $159. These are published offer terms, not a completed order or verification of how quickly a clinician responds. Product offer and billing-unit wording.

The three-month description does not establish that every person should receive the serum for that duration. Our commercial comparison keeps the product, price unit and professional assessment separate instead of creating an unsupported monthly value ranking.

Alloy says a menopause-trained doctor reviews medical history to decide whether the product is appropriate. That documents an advertised evaluation pathway. It does not show what a particular review would conclude, prove the absence of adverse effects or mean a facial estrogen has an approved menopausal-symptom indication. Access description.

FDA explains the premarket-review limitation of compounded medicines, and its menopause page identifies marketed estriol drugs as compounded and not approved. A prescription symbol or physician-access feature does not alter that distinction. The Midi review applies the same standard to a separately documented cream. FDA compounding context.

The most informative request is for evidence concerning this serum, its actual formulation and the specific outcome being claimed. It is also reasonable to ask which supplied record confirms the ingredients and which professional handles clinical follow-up. These questions preserve uncertainty without assuming the product is either ineffective or appropriate for every reader.

The photograph guide explains why an appearance image cannot settle hormone safety. The Time Out review describes another offer with its own limits. Neither a comparison order nor a cream study on a serum page answers the individual clinical question.